Search
Displaying 511–520 of 664 for “retinitis clinical trial”
-
Beacon Stories
“If someone like me, a woman with retinitis pigmentosa and a part-time job, can leave a legacy gift, you can too! And trust me, it feels really, really good to know that part of your life’s work will contribute to something meaningful for future generations.”
-
The VISIONS Team is working hard to secure some of the world’s best researchers and clinicians in the field of retinal diseases to speak at VISIONS2018.
-
Beacon Stories
Jen Walker was diagnosed with retinitis pigmentosa at 14 years old and didn’t feel ready to meet others with retinal diseases until many years later. Jen now wants to connect with others and raise awareness for the fighting blindness community.
-
Hannah Dreams Big Despite Vision Loss
Beacon StoriesHannah has always had dreams of starting her own fashion line. And despite being diagnosed with retinitis pigmentosa at the age of 15, she recently began an intimate company, Watson & Wilma.
-
Beacon Stories
Susan, who has retinitis pigmentosa, went through many tests in search of learning more about her eye disease. Once she enrolled in the My Retina Tracker® (MRT) testing program, Susan was provided with comprehensive results and a clear diagnosis, giving her clarity and hope.
-
Jack Sees a Different Life after LUXTURNA
Beacon StoriesJack Hogan was diagnosed with retinitis pigmentosa at only two-and-a-half years old. But with the help of connections made with the Foundation, Jack became the first-ever recipient of the FDA-approved gene therapy known as LUXTURNA.
-
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Foundation NewsBipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Research NewsFrancois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
Foundation NewsMore than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
-
Foundation Fighting Blindness Urges Congress to Pass ‘Eye-Bonds’ Legislation
Foundation NewsBill Introduced in U.S. House Would Speed Up Cures for Blindness
